🔗 Share this article

Given that America undertakes historic revisions to its vaccine guidelines, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by questioning Covid shots throughout the pandemic and has focused upon alleged deaths after COVID-19 immunization in her brief time at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Immunization Schedule

Public health authorities were set to announce sweeping changes to the childhood vaccine schedule in December, synchronizing the US with Denmark’s national calendar, it is understood – a significant shift that would put the US out of alignment with a large portion of the world with insufficient data for benefit. The planned update has been delayed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to lead the division this calendar year.

A Shift at the Regulatory Body

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics centers as Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a renewed priority upon dismantling previously authorized vaccines at the FDA.

Høeg has repeatedly called for ending specific childhood shot schedules in the US to become more in line with the Danish model, a country with comprehensive healthcare and a number of inhabitants roughly the population of Wisconsin’s.

In her initial comments, she has continued to focus on vaccination policy – typically the responsibility of Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Doubts Over Expertise

The appointee has no obvious background in drug development, approval processes or administrative roles, which has been typical for previous heads of the biologics center. She has served at the FDA as a senior adviser to the agency head and CBER since spring.

“She appears not to have the requisite experience” for overseeing the CDER, said Dr. Jonathan Howard. “She’s never run a scientific study. She lacks experience in running a major agency. She lacks background in pharmaceutical oversight.”

Former heads of CBER would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who led the center have had.”

The drug center has an enormous workload at the FDA, the former commissioner pointed out.

“Everybody just pays attention on the new drug program, but the generic program authorizes numerous generic medications. There’s a biosimilars program, OTC medication office and more, and every single one need to be supervised,” she said. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership component to the position, which manages in excess of 5,000 personnel. “It is a enormous leadership role, if you perform it correctly,” she said.

Response and Controversial Policies

Regarding questions about Høeg’s credentials and whether this appointment indicates increased cooperation among agency officials on immunizations, a representative stated that the “questions stem from incorrect presumptions”.

“Her experience matches the duties of her job,” the official explained, noting the period Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched expedited review system, a disputed one-day drug-approval program that reportedly concerned her former heads. “By what process are these medications being chosen for this expedited pathway? Who takes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he said, “the FDA seems to be moving towards laxer rules of pharmaceuticals, aside from vaccines.”

Documented Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if concerning, history, critics said. She authored a analysis using unconfirmed public submissions to assess the incidence of heart inflammation after Covid immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the incoming government included altering regulations for novel immunizations and discontinuing “non-essential” vaccines, she said after the election on a online show. At the FDA, Høeg has according to sources suggested barring adolescent males from receiving Covid vaccinations.

“She is an complete true believer who begins with her conclusions and works backwards to accommodate the data in a very deceptive, fraudulent fashion,” Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg became part of fellow skeptics, {like|